Latigo Biotherapeutics, Inc. (“Latigo”) today announced that the first participant has been dosed in its Phase 1 clinical trial of LTG-305, a potential best-in-class non-opioid therapeutic candidate for the treatment of chronic pain.
ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the formation of a scientific and patient advisory board comprised of leading experts and advocates in thyroid eye disease (TED)
CAP-003 achieved best-in-class GCase increases in NHPs exceeding levels needed for normalizing activity in patients
Warner Biddle Appointed as Chief Executive Officer and to Board of Directors, Bringing Over 30 Years of Commercial, Product Planning and Franchise Leadership Experience, Including Successful Launches for CAR T Pioneer in Hematology
In a recent article in Endpoints, Astellas highlights its work in gene therapy and commitment to rare diseases, including its collaboration with Kate Therapeutics.
Latigo Biotherapeutics Inc. (“Latigo”), a clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target pain at its source, today announced the appointment of Tim Lugo as chief financial officer (CFO). In addition, Latigo has appointed Beth Seidenberg, M.D., and Jim Tananbaum, M.D., to its board of directors. These appointments bring deep expertise and leadership as Latigo scales to rapidly advance its lead clinical programs.
Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced the close of an oversubscribed $325 million Series C financing round. The funding round included new investors ARCH Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVentures (NVIDIA’s venture capital arm), Luma Group, funds and accounts advised by T. Rowe Price Associates, Inc., Rock Springs Capital, among others, with ongoing support from existing investors the Parker Institute for Cancer Immunotherapy (PICI), SoftBank Vision Fund 2, Bristol-Myers Squibb Company, Westlake Village BioPartners, Kleiner Perkins, Byers Capital, and Hitachi Ventures.
Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies, today announced the presentation of clinical data from VIVID 1 (VGA039 Investigation in Von Willebrand Disease), a Phase 1 clinical study of VGA039 in healthy volunteers. VGA039 is designed to be a universal hemostatic therapy for numerous bleeding disorders and potentially the first subcutaneous therapy for von Willebrand disease (VWD). The VGA039 clinical data was presented today in an oral presentation at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), taking place on June 22-26 in Bangkok, Thailand.
Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, announced the presentation of clinical data for ELA026 in secondary hemophagocytic lymphohistiocytosis (sHLH), a life-threatening hyperinflammatory condition.
Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today that it will host a sponsored symposium to present the largest and most diverse set of data to date from a cohort of 50 patients treated with the CAR in KYV-101, an autologous, fully human anti-CD19 CAR T-cell immunotherapy. The data support the differentiated safety profile of the CAR in various indications, including a 30-patient data set that spans >28 day follow-up in various autoimmune disease patients with early efficacy data. A 12-month follow-up of the first patient treated with KYV-101 for myasthenia gravis will also be presented.
